Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728728 · ClinicalTrials.gov registry record · Phase 2
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT00728728: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT00728728 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728728, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Dietary Supplement: Pregnenolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728728
The ClinicalTrials.gov registry entry for NCT00728728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00728728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728728 about?
NCT00728728 is a clinical study titled "Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia". This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
What is the current status of trial NCT00728728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2009-12. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00728728?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Dietary Supplement: Pregnenolone (DRUG).
Who is sponsoring clinical trial NCT00728728?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.